OS Therapies Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by OS Therapies Incorporated on September 30, 2025. The Company is an emerging growth company incorporated in Delaware, with principal executive offices in Grasonville, Maryland. Its common stock trades under the symbol OSTX on the NYSE American.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes and Events
The primary event reported is the filing of a Prospectus Supplement with the SEC on September 30, 2025. This supplement is part of a registration statement on Form S-3 (File No. 333-289443) declared effective on August 12, 2025. The supplement covers the resale from time to time of up to 4,373,043 shares of the Company's common stock by selling stockholders referenced in the document.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or an outlook for future periods. The report focuses on the legal opinion of counsel, Olshan Frome Wolosky LLP, regarding the legality of the shares to be resold, which is attached as Exhibit 5.1. No specific risks or contingencies are detailed in the text of this 8-K.
Key Facts for Investor Verification
- Verify the identity of the selling stockholders and their ownership stakes prior to the resale.
- Review the full Prospectus Supplement (File No. 333-289443) for details on the use of proceeds, if any, and the terms of the resale.
- Confirm the impact of the potential resale of 4,373,043 shares on the Company's total outstanding share count and dilution.
- Check the attached legal opinion (Exhibit 5.1) for any conditions or limitations on the share resale.